Diseases /

Pituitary Gland Adenoma

Back to Diseases List

Overview

NCI Definition: A non-metastasizing tumor that arises from the adenohypophysial cells of the anterior lobe of the pituitary gland. The tumor can be hormonally functioning or not. The diagnosis can be based on imaging studies and/or radioimmunoassays. Due to its location in the sella turcica, expansion of the tumor mass can impinge on the optic chiasm or involve the temporal lobe, third ventricle and posterior fossa A frequently associated physical finding is bitemporal hemianopsia which may progress to further visual loss. [1]

Pituitary gland adenomas most frequently harbor alterations in GNAS, PRKDC, FANCA, PTPRD, and KMT2D [2].

Most Commonly Altered Genes in Pituitary Gland Adenoma

GNAS Mutation, PRKDC Mutation, FANCA Mutation, KMT2D Mutation, and ARID1B Mutation are the most common alterations in pituitary gland adenoma [2].

Top Alterations in Pituitary Gland Adenoma

Clinical Trials

View Clinical Trials for Pituitary Gland Adenoma

Disease Details

Synonyms
Pituitary Adenoma, Adenoma of the Pituitary, Adenoma of Pituitary Gland, ADENOMA, ANTERIOR LOBE PITUITARY GLAND, BENIGN, Adenoma of the Pituitary Gland, Adenoma of Pituitary
Parent(s)
Anterior Pituitary Gland Endocrine Neoplasm
Children
Non-Functioning Pituitary Gland Adenoma, Atypical Pituitary Gland Adenoma, Prolactin-Producing Pituitary Gland Adenoma, Growth Hormone-Producing Pituitary Gland Adenoma, Functioning Pituitary Gland Adenoma, ACTH-Producing Pituitary Gland Adenoma, and TSH-Producing Pituitary Gland Adenoma
OncoTree Name
Pituitary Adenoma
OncoTree Code
PTAD

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.